INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on November 23, 2022. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing references specific financial data from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022:
- Stockholders' Equity: $1,287,224
- Nasdaq Minimum Requirement: $2,500,000
- Alternative Compliance Standards: The Company did not meet the alternative standards of $35 million in market value of listed securities or $500,000 in net income from continuing operations.
The filing text does not provide current values for revenue, profit, cash flow, margins, debt, or liquidity beyond the referenced equity figure.
Material Changes and Events
The primary event reported is the receipt of a Notice of Delisting or Failure to Satisfy a Continued Listing Rule. The Company is currently non-compliant with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity. The Company's common stock continues to trade on The Nasdaq Capital Market pending the outcome of the compliance process.
Outlook, Risks, and Management Commentary
Compliance Timeline:
- Plan Submission Deadline: January 7, 2023 (45 calendar days from the Notice).
- Compliance Period: If a plan is accepted, the Company may receive an extension of up to 180 calendar days to evidence compliance.
Risks and Contingencies:
- There is no assurance that the Company's plan to regain compliance will be accepted by Nasdaq.
- Even if accepted, there is no assurance the Company will successfully regain compliance within the allotted time.
- Failure to regain compliance or satisfy other listing requirements could result in delisting.
- The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel, which would stay any suspension pending the hearing.
Key Facts for Investor Verification
- Verify the Company's current stockholders' equity and whether it has improved since the September 30, 2022, reporting date.
- Monitor the submission of the compliance plan to Nasdaq by the January 7, 2023 deadline.
- Track the status of the Company's market value of listed securities and net income to assess alternative compliance paths.
- Review any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq.